GUIDE demonstrates: Hit hard and early in psoriasis Presented ByProf. Knut Schäkel, University Clinic Heidelberg, Germany TrialPhase 3, GUIDE ConferenceAAD 2024 22 April, 2024 16:36
Robust long-term efficacy of bimekizumab in psoriasis Presented ByProf. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA TrialBE BRIGHT ConferenceAAD 2024 22 April, 2024 16:09
Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2 Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 2, STRIDE ConferenceAAD 2024 22 April, 2024 16:01
Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells Presented ByProf. Andrew Blauvelt, Oregon Medical Research Center, USA TrialPhase 2, KNOCKOUT ConferenceAAD 2024 22 April, 2024 15:41
SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases? Presented ByAllison Holt, UMass Chan Medical School, USA ConferenceAAD 2024 22 April, 2024 15:06
Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT Trial ExpertDr Andrew Blauvelt TrialPhase 2, KNOCKOUT ConferenceAAD 2024 22 April, 2024 12:12
Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT trial ExpertDr Andrew Blauvelt, Oregon Medical Research Center, USA TrialPhase 2, KNOCKOUT 25 March, 2024 11:53
High-dose subcutaneous spesolimab prevents GPP flares up to week 48 Presented ByProf. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany TrialPhase 2, Effisayil 2 ConferenceEADV 2023 28 November, 2023 12:23
Drug survival of guselkumab and risankizumab seems superior to other biologics Presented ByDr Zenas Yiu, University of Manchester, UK TrialBADBIR ConferenceEADV 2023 28 November, 2023 12:04
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis Presented ByDr Robert Bissonnette, Innovaderm Research, Canada TrialPhase 2, FRONTIER 1 ConferenceEADV 2023 28 November, 2023 11:57
Women with psoriasis face increased adverse effects with systemic therapy Presented ByDr Fabio Verardi, University Hospital Zurich, Switzerland ConferenceEADV 2023 28 November, 2023 09:50
Strategies for Early Psoriatic Arthritis Recognition in Psoriasis Patients: GRAPPA Survey Findings TrialReview study, GRAPPA 20 October, 2023 12:15
PsA patients: highest risk of developing NAFLD Presented ByMr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK ConferenceEULAR 2023 31 July, 2023 06:09
Switching to risankizumab successful in IL-17 inhibitor non-responders Presented ByProf. Richard Warren, University of Manchester, UK TrialPhase 3, aIMM study ConferenceAAD 2023 15 May, 2023 11:56
Novel, selective TYK2 inhibitor shows promise for psoriasis Presented ByProf. April Armstrong, Keck School of Medicine of University of California, LA, USA TrialPhase 2 ConferenceAAD 2023 15 May, 2023 11:51
Genital psoriasis: high prevalence, often underdiagnosed Presented ByDr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany ConferenceEADV 2022 5 November, 2022 11:12
Novel oral psoriasis drug maintains efficacy over 2 years Presented ByProf. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA TrialPhase 3, POETYK-PSO-1 ConferenceEADV 2022 5 November, 2022 10:36
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability Presented ByDr Kim A. Papp, Probity Medical Research, Canada TrialPhase 3, COMFORT ConferenceEADV 2022 5 November, 2022 10:32
Systemic treatment for psoriasis: what is on the horizon? Presented ByProf. Diamant Thaci , University of Lübeck, Germany ConferenceSPIN 2022 26 August, 2022 10:45
Topical therapy in psoriasis: an important partner in combination therapy Presented ByProf. Peter van de Kerkhof, Radboud University Medical Centre, the Netherlands ConferenceSPIN 2022 26 August, 2022 10:40
GPP flares: pronounced undertreatment is common Presented ByDr Wendell Valdecantos , Boehringer Ingelheim Pharmaceuticals, CT, USA ConferenceSPIN 2022 26 August, 2022 10:38
All patients with GPP benefit from IL-36 inhibitor therapy TrialPhase 2, Effisayil 1 ConferenceSPIN 2022 26 August, 2022 10:37
IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab TrialPhase 3, BE RADIANT ConferenceSPIN 2022 26 August, 2022 10:35
Greater PASI reductions lead to less impairment in social and sexual life TrialPhase 3, VOYAGE 1, VOYAGE 2 ConferenceSPIN 2022 26 August, 2022 10:32
Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas Presented ByDr Marieke Seyger , Radboud University Medical Centre, the Netherlands TrialPhase 3, IXORA-PEDS ConferenceSPIN 2022 26 August, 2022 10:30
Psoriasis patients see great benefit in achieving complete skin clearance Presented ByProf. Matthias Augustin , University Medical Centre Hamburg, Germany ConferenceSPIN 2022 26 August, 2022 10:25
Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib Presented ByProf. Mark Lebwohl , Icahn School of Medicine at Mount Sinai, NY, USA TrialPhase 3, POETYK PSO-1, POETYK PSO-2 ConferenceSPIN 2022 26 August, 2022 09:50
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab Presented ByProf. April Armstrong, Keck School of Medicine of USC, CA, USA TrialPhase 3, CIMPASI-1, CIMPASI-2 ConferenceSPIN 2022 26 August, 2022 09:47
Dose tapering in psoriasis is associated with a low relapse rate Presented ByDr Juan Raul Castro Ayarza , Medicarte, Colombia ConferenceSPIN 2022 26 August, 2022 09:43
SPIN 2022 Highlights Podcast Presented ByRobert van den Heuvel, Medicom ConferenceSPIN 2022 19 July, 2022 00:24
Dermatology diseases need the highest doses of biologics Presented ByDr Charlotte Greif, Beth Israel Deaconess Medical Center, USA ConferenceAAD 2022 17 May, 2022 12:24
New insights into psoriasis comorbidity Presented ByProf. Joel Gelfand, University of Pennsylvania, USA ConferenceAAD 2022 17 May, 2022 12:12
Long-term psoriasis treatment with bimekizumab results in maintained efficacy Presented ByProf. Kenneth Gordon, Medical College of Wisconsin, USA ConferenceAAD 2022 17 May, 2022 12:09
Novel developments in topical psoriasis therapy Presented ByProf. April Armstrong, University of Southern California Keck School of Medicine, USA TrialPhase 3, PSOARING; PSO-LONG ConferenceAAD 2022 17 May, 2022 12:06
JAK inhibitors: A risk assessment Presented ByProf. Brett King, Yale School of Medicine, USA ConferenceAAD 2022 17 May, 2022 10:59
Intestinal microbe-preparation: Modest activity but safe for mild psoriasis Presented ByDr Douglas Maslin TrialPhase 2 ConferenceAAD 2022 17 May, 2022 10:40
International consensus reached on methotrexate dosing for psoriasis JournalJAMA Dermatology 7 April, 2022 22:30
Potential biomarker discovered for treatment response to ustekinumab Presented ByMr Shane Solanky, King’s College London, UK ConferencePFGC 2021 3 February, 2022 15:46
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis Presented ByDr Nikolai Loft, Copenhagen University Hospital, Denmark ConferencePFGC 2021 3 February, 2022 15:08
Secukinumab also tolerable in paediatric psoriasis patients Presented ByProf. Michael Sticherling, University Erlangen–Nürnberg, Germany ConferencePFGC 2021 3 February, 2022 11:22
High treatment success with ixekizumab in patients with psoriasis and diabetes Presented ByDr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark TrialPhase 3, UNCOVER ConferencePFGC 2021 3 February, 2022 11:15
The Yin and Yang of opposing vectors: an explanation for side effects of biologics Presented ByProf. Curdin Conrad, Lausanne University Hospital, Switzerland ConferencePFGC 2021 3 February, 2022 11:07
DLQI scores underestimated during lockdowns? Presented ByDr Ali Alsharqi, St. Vincent’s University Hospital, Ireland ConferencePFGC 2021 3 February, 2022 10:34
TNF blockers likely beneficial for psoriatic patients with COVID-19 Presented ByProf. Catherine Smith, King’s College London, UK TrialPsoProtect ConferencePFG 2021 2 February, 2022 15:42
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion Presented ByDr Ali Al-Janabi, University of Manchester, UK ConferencePFGC 2021 2 February, 2022 15:22
IL-36 gene expression in GPP lesions reduced by spesolimab Presented ByDr Ahmed Farag ConferencePFGC 2021 2 February, 2022 15:09
Inhibition of heat shock protein: A novel way to treat psoriasis? Presented ByDr Anne Bregnhøj, Aarhus University Hospital, Denmark ConferencePFGC 2021 2 February, 2022 15:02
Guselkumab shows highest drug survival among systemic treatments Presented ByDr Zenas Yiu, University of Manchester, UK ConferencePFGC 2021 2 February, 2022 14:55
Risankizumab superior to ustekinumab in skin histopathology scores Presented ByDr Kathleen Smith TrialPhase 3, UltiMMa-1 trial ConferencePFGC 2021 2 February, 2022 14:49
Tapering biologics: No alarming signs of increased anti-drug antibodies Presented ByDr Juul van den Reek , Radboudumc, the Netherlands TrialPhase 4, CONDOR ConferencePFGC 2021 2 February, 2022 14:43
Intermediate monocytes are possible predictors of response to secukinumab Presented ByDr Jonathan Hardman-Smart, King’s College London, UK TrialPhase 3, SIGNATURE ConferencePFGC 2021 2 February, 2022 14:34
Gut microbiota of psoriasis patients: less diverse and reduced functionality Presented ByDr Tanja Todberg, University of Copenhagen, Denmark ConferencePFGC 2021 2 February, 2022 14:29
Psoriasis associated with a higher cancer risk Presented ByMr Alex Trafford, University of Manchester, UK ConferencePFGC 2021 2 February, 2022 14:23
Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status Presented ByDr Ravi Ramessur, King’s College London, UK ConferencePFGC 2021 2 February, 2022 14:20
Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation Presented ByDr Niamh Kearney, St. Vincent’s University Hospital, Ireland ConferencePFGC 2021 2 February, 2022 14:16
HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario Presented ByDr Oras Alabas, University of Manchester, UK ConferencePFGC 2021 2 February, 2022 14:05
Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis Presented ByDr Teresa Tsakok, King’s College London, UK ConferencePFGC 2021 2 February, 2022 13:37
Dermatologists and psoriasis patients call for specialized care to prevent heart disease JournalJAMA Dermatology 26 January, 2022 16:22
One week enough to clear pustular psoriasis in half of patients after experimental infusion JournalThe New England Journal of Medicine 22 December, 2021 23:00
PFGC 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferencePFGC 2021 22 December, 2021 08:12
Support for therapeutic drug monitoring with infliximab maintenance therapy JournalJAMA 21 December, 2021 17:19
Experimental cream improves plaque psoriasis but can spark local side effects, headaches JournalThe New England Journal of Medicine 10 December, 2021 18:51
Psoriasis tied to small increase in risk of venous thromboembolism, peripheral vascular disease JournalJAMA Dermatology 2 December, 2021 17:40
Comparing routes of administration of methotrexate in psoriasis patients Presented ByMr Ishan Agrawal, Siksha O Anusandhan University Bhubaneswar, India ConferenceICD 2021 2 December, 2021 17:24
ICD 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceICD 2021 29 November, 2021 09:20
TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis Presented ByProf. Richard Warren, University of Manchester, UK TrialPhase 3, POETYK PSO ConferenceEADV 2021 18 November, 2021 13:31
Tapinarof cream for psoriasis leads to high clearance rates and remittive effect Presented ByDr Linda Stein Gold, Henry Ford Health System, USA TrialPSOARING 3 ConferenceEADV 2021 18 November, 2021 13:30
Existing and upcoming small molecules in psoriasis Presented ByDr Enikö Sonkoly , Karolinska University Hospital, Sweden TrialPOETYK PSO; PSOARING ConferenceEADV 2021 18 November, 2021 13:19
Treating psoriasis during pregnancies Presented ByProf. Mahira Hamdy El Sayed, Ain Shams University, Egypt ConferenceEADV 2021 18 November, 2021 13:18
A patient-related approach to freedom of disease Presented ByElfie Deprez , Ghent University Hospital, Belgium ConferenceEADV 2021 18 November, 2021 13:17
Ixekizumab superior to secukinumab in real-world psoriasis study Presented ByDr Caterina Cariti, University of Turin, Italy ConferenceEADV 2021 18 November, 2021 13:16
Nail psoriasis: An important target to be treated Presented ByProf. Peter van de Kerkhof , Radboudumc, the Netherlands ConferenceEADV 2021 18 November, 2021 13:15
Grand debate: Is psoriasis a systemic or skin-only disease? Presented ByProf. Brian Kirby & Prof. Stefano Piaserico ConferenceEADV 2021 18 November, 2021 13:14
EADV 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom TrialPSOARING 3, JADE-DARE, HEADS UP ConferenceEADV 2021 19 October, 2021 00:08
Live varicella-zoster vaccine safe, effective with TNF inhibitors JournalAnnals of Internal Medicine 29 September, 2021 23:18
Could steroid treatment speed recovery from infliximab-induced liver injury? JournalJournal of Hepatology 28 September, 2021 17:12
Unresolved needs for patients with PsA despite growing therapeutic options ConferenceWPPAC 2021 17 September, 2021 13:46
PsoBarrier EU: Large survey evaluating quality of care in Europe Presented ByDr Anna Langenbruch, Universitätsklinikum Hamburg-Eppendorf, Germany TrialPsoBarrier EU ConferenceWPPAC 2021 17 September, 2021 13:43
Bridging the gap between patients and access to psoriasis specialists Presented ByDr Silvia Fernandez Barrio, AEPSO, Argentina ConferenceWPPAC 2021 17 September, 2021 13:42
Psoriasis and PsA in transgender adults on hormone therapy Presented ByMs Julia Gao, Fenway Health, MA, USA ConferenceWPPAC 2021 17 September, 2021 13:41
Psoriasis: New disease severity classification Presented ByProf. Lone Skov, University of Copenhagen, Denmark ConferenceWPPAC 2021 17 September, 2021 13:39
Immune checkpoint inhibitors in patients with pre-existing psoriasis ConferenceWPPAC 2021 17 September, 2021 13:35
Psoriasis registries yield important data about COVID-19 Presented ByDr Satveer Mahil, St John’s Institute of Dermatology, UK ConferenceWPPAC 2021 17 September, 2021 12:35
COVID-19 affects patients and care Presented ByProf. Peter van de Kerkhof, Radboudumc, the Netherlands ConferenceWPPAC 2021 17 September, 2021 12:33
Vaccination feasible in people with psoriatic disease Presented ByProf. Ulrich Mrowietz, University Medical Centre Schleswig-Holstein, Germany ConferenceWPPAC 2021 17 September, 2021 12:30
Low COVID-19 risk for patients with psoriasis on biologic treatment Presented ByDr Jorge Georgakopoulos, University of Toronto, Canada ConferenceWPPAC 2021 17 September, 2021 12:28
Psoriasis: Disrupted gut-skin axis Presented ByDr Mariusz Sikora, Medical University of Warsaw, Poland ConferenceWPPAC 2021 17 September, 2021 12:22
Psoriasis associated with increased duodenum inflammation Presented ByProf. Maria Lampinen, Uppsala University, Sweden ConferenceWPPAC 2021 17 September, 2021 12:20
Whole-exome sequencing to study the underlying pathogenesis of psoriasis Presented ByMr Sigurgeir Olafsson, University of Cambridge, UK ConferenceWPPAC 2021 17 September, 2021 12:19
Potential role of inflammation in cardiovascular comorbidity Presented ByDr Alexander Egeberg, Herlev and Gentofte Hospital, Denmark TrialPhase 3, CANTOS, CIRT ConferenceWPPAC 2021 17 September, 2021 11:13
Psoriasis: New treatments and current pipeline Presented ByProf. Kristian Reich, Dermatologikum Hamburg, Germany ConferenceWPPAC 2021 17 September, 2021 11:08
Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab Presented ByProf. Hervé Bachelez, Hôpital Saint-Louis, France TrialPhase 2, Effisayil 1 ConferenceWPPAC 2021 17 September, 2021 11:04
Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis TrialPhase 3, POETYK PSO-1, POETYK PSO-2 ConferenceWPPAC 2021 17 September, 2021 10:59
Certain biologics may boost serious infection risk in patients with psoriasis JournalJAMA Dermatology 30 July, 2021 21:28
Methotrexate use tied to weakened antibody response after first Pfizer-BioNTech vaccine shot JournalLancet Rheumatology 21 July, 2021 16:05
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on Presented ByProf. April W. Armstrong, University of Southern California, USA ConferenceAAD VMX 2021 7 June, 2021 13:32
Psoriasis: The treatment armamentarium continues to grow Presented ByProf. Bruce Strober, Yale University, CT, USA ConferenceAAD VMX 2021 7 June, 2021 13:32
Psoriasis management in times of COVID-19: the knowledge is growing steadily Presented ByProf. Joel Gelfand, University of Pennsylvania Perelman School of Medicine, PA, USA ConferenceAAD VMX 2021 7 June, 2021 13:31
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics Presented ByProf. Nehal N. Mehta, National Heart, Lung, and Blood Institute, MD, USA ConferenceAAD VMX 2021 7 June, 2021 13:30
Convincingly low levels of infections with long-term tildrakizumab TrialreSURFACE 1 and 2 ConferenceAAD VMX 2021 7 June, 2021 13:15
Small molecule effective in moderate-to-severe psoriasis Presented ByProf. April Armstrong, Keck School of Medicine at UCLA, CA, USA TrialPhase 3, POETYK PSO-1 and 2 ConferenceAAD VMX 2021 7 June, 2021 10:50
Bimekizumab superior to secukinumab in psoriasis Presented ByProf. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany TrialPhase 3, BE RADIANT ConferenceAAD VMX 2021 7 June, 2021 10:47
Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients Presented ByProf. Leon Kircik, Icahn School of Medicine at Mount Sinai Medical Center, USA ConferenceAAD VMX 2021 7 June, 2021 10:43
Therapeutic drug monitoring has little value during infliximab induction JournalJAMA 4 May, 2021 18:05
New psoriasis injection bests secukinumab, adalimumab in separate tests JournalThe New England Journal of Medicine 23 April, 2021 18:50
Switch from adalimumab to its biosimilar not tied to drug retention in psoriasis patients JournalJAMA Dermatology 16 April, 2021 23:04
Risankizumab long-term risk-benefit profile for moderate to severe psoriasis JournalJournal of the American Academy of Dermatology 11 March, 2021 23:05
Real-world data on brodalumab affirms efficacy and fast onset of action Presented ByDr Ralph Von Kiedrowski TrialLIBERO ConferenceEADV 2020 17 December, 2020 14:35
Bimekizumab in psoriasis: Up-and-coming Presented ByProf. Bruce Strober, Yale University, USA TrialPhase 3, BE VIVID ConferenceEADV 2020 17 December, 2020 14:34
Biologic psoriasis treatment and COVID-19 risk: Contradictory results Presented ByDr Anne-Claire Fougerousse; Dr Giovanni Damiani ConferenceEADV 2020 17 December, 2020 14:12
Selective IL-23 blocker shows potential in psoriasis treatment Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 3, OASIS-2 ConferenceEADV 2020 17 December, 2020 13:44
Promising results with nanobody treatment in psoriasis Presented ByDr Kim A. Papp, Probity Medical Research, Canada TrialPhase 2 ConferenceEADV 2020 17 December, 2020 13:40
Efficacious non-steroidal topical for psoriasis Presented ByProf. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA TrialPhase 3, PSOARING ConferenceEADV 2020 17 December, 2020 13:28
Risankizumab improves patient-reported outcomes in moderate to severe psoriasis JournalJAMA Dermatology 22 October, 2020 16:09
Improvement of coronary-artery-plaque lipid-rich necrotic core seen with biologic therapy of psoriasis JournalCirculation: Cardiovascular Imaging 15 September, 2020 21:31
Selective IL-23 blocker safe in elderly psoriasis patients Presented ByProf. Peter van de Kerkhof, Radboudumc, the Netherlands TrialreSURFACE ConferenceAAD 2020 19 August, 2020 13:18
Psoriasis therapy for children and pregnancies Presented ByProf. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA TrialCRIB, CADMUS, IXORA-PEDS ConferenceAAD 2020 6 August, 2020 08:03
Biologic psoriasis treatment to lower cardiovascular risk? Presented ByProf. Joel Gelfand, University of Pennsylvania, USA ConferenceAAD 2020 6 August, 2020 08:01
A new topical PDE-4 inhibitor effective in psoriasis Presented ByProf. Mark Lebwohl ConferenceAAD 2020 6 August, 2020 08:00
IL-17A and IL-17F blockade remarkably effective in psoriasis Presented ByProf. Kristian Reich; Prof. Kenneth B. Gordon TrialBE VIVID and BE READY ConferenceAAD 2020 6 August, 2020 07:09
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis Presented ByProf. Richard B. Warren TrialIMMerge ConferenceAAD 2020 6 August, 2020 07:07
Tape stripping – a painless way to distinguish AD and psoriasis? Presented ByDr Robert Bissonnette, Innovaderm Research, Canada ConferenceAAD 2020 6 August, 2020 07:05
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients? Presented ByDr Nikolai Klebanov , Brigham and Women’s Hospital, USA ConferenceAAD 2020 6 August, 2020 07:01
Lowest risk of infection after therapy with an IL-12/IL-23 blocker Presented ByDr Yinzhu Jin, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA TrialCohort study ConferenceACR 2019 4 February, 2020 23:42
Psoriasis onset determines sequence of symptoms Presented ByProf. Umut Kalyoncu, Hacettepe University, Turkey ConferenceACR 2019 4 February, 2020 23:07
IL-17A blocker effective in paediatric psoriasis patients Presented ByDr Kim Papp, Probity Medical Research, Canada TrialPhase 3, IXORA-PEDS ConferenceEADV 2019 9 December, 2019 20:51
Biologics: increasingly used in paediatric dermatology Presented ByProf. Marieke Seyger, Radboud University Nijmegen, the Netherlands ConferenceEADV 2019 9 December, 2019 15:16
Comorbidities more common in chronic urticaria, psoriasis, and AD Presented ByDr Karsten Weller, Charité University Hospital, Germany ConferenceEADV 2019 9 October, 2019 20:40
IL-17 blocker: effective and safe in patients with comorbidities Presented ByDr Alice Gottlieb, Tufts University School of Medicine, USA ConferenceEADV 2019 9 October, 2019 20:19
Reduced sleep quality in dermatoses influenced by itch and pain Presented ByDr Karolina Kaaz, Wroclaw Medical University, Poland ConferenceEADV 2019 9 October, 2019 19:58
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker Presented ByProf. Diamant Thaçi, University of Lübeck, Germany TrialESPRIT ConferenceEADV 2019 9 October, 2019 19:23
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis Presented ByDr Daniel Nieto, La Paz Hospital, Spain ConferenceEADV 2019 9 October, 2019 18:25
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome Presented ByDr Alice Gottlieb, Tufts University School of Medicine, USA TrialreSURFACE 1 and 2 ConferenceEADV 2019 9 October, 2019 17:28
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints Presented ByProf. Diamant Thaçi, University of Lübeck, Germany ConferenceEADV 2019 9 October, 2019 16:30
Certolizumab pegol efficacious for head and neck psoriasis Presented ByProf. Peter van de Kerkhof, Radboud University, the Netherlands TrialPhase 3, CIMPASI-1 and CIMPASI-2 ConferenceEADV 2019 9 October, 2019 15:02
No hint of teratogenicity through ixekizumab Presented ByProf. Alexander Egeberg, Herlev and Gentofte Hospital, Denmark TrialPSOLAR ConferenceEADV 2019 9 October, 2019 14:32
Novel selective IL-23 blocker highly effective over 2 years TrialPhase 3, IMMhance ConferenceWCD 2019 26 August, 2019 11:52
Favourable safety profile of long-term use of ixekizumab Presented ByProf. Kristian Reich, Georg-August-University Göttingen, Germany ConferenceSPIN 2019 21 June, 2019 22:50
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies Presented ByDr Sandra Philipp, Charité-Universitätsmedizin Berlin, Germany TrialPhase 3, AMAGINE ConferenceSPIN 2019 21 June, 2019 21:59
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity Presented ByDr Gayle van der Kraaij, Amsterdam UMC, the Netherlands ConferenceSPIN 2019 21 June, 2019 20:57
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients Presented ByDr Sandra Phillip, Charité-Universitätsmedizin Berlin, Germany TrialPhase 3, CADMUS Jr ConferenceSPIN 2019 21 June, 2019 19:59
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis? Presented ByProf. Kristian Reich, Georg-August-University Göttingen, Germany TrialECLIPSE ConferenceSPIN 2019 21 June, 2019 18:23
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis Presented ByProf. Peter van de Kerkhof, Radboud University Medical Center, the Netherlands ConferenceSPIN 2019 21 June, 2019 18:02
ABP501 biosimilar for adalimumab: What you need to know Presented ByProf. Brian Kirby, St Vincent's Hospital, Dublin, Ireland ConferenceSPIN 2019 21 June, 2019 17:24
Switching infliximab biosimilars safe in treating chronic plaque psoriasis ConferenceSPIN 2019 21 June, 2019 16:26
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis Presented ByDr Nehal Mehta; Prof. Emma Guttman-Yassky TrialNHANES ConferenceSPIN 2019 21 June, 2019 14:38
Atopic dermatitis and psoriasis: on a spectrum? Presented ByProf. Emma Guttman-Yassky, Mount Sinai Medical School, USA ConferenceSPIN 2019 21 June, 2019 13:39
Small molecules, apremilast, and TYK2 Presented ByProf. Richard Langley, Dalhousie University, Canada TrialESTEEM, PALACE, LIBERATE ConferenceSPIN 2019 21 June, 2019 09:45
IBD risk of treatment with IL-17 antagonists Presented ByDr Wolfgang Eigner, Medical University of Vienna, Austria ConferenceECCO 2019 9 May, 2019 14:37
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies 29 April, 2019 12:50
Secukinumab maintains improvements in psoriasis through 5 years of treatment Presented ByProf. Richard Langley, Dalhousie University, Canada TrialERASURE/FIXTURE ConferenceAAD 2019 19 April, 2019 23:10
Plaque psoriasis – Efficacy of guselkumab TrialPhase 3, VOYAGE 1, VOYAGE 2 ConferenceAAD 2019 19 April, 2019 20:06
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis Presented ByDr Andrew Blauvelt, Oregon Medical Research Center, USA TrialBE ABLE ConferenceAAD 2019 19 April, 2019 19:24
Serlopitant reduces pruritus associated with psoriasis Presented ByDr David Pariser, Pariser Dermatology Specialists Virginia, USA ConferenceAAD 2019 19 April, 2019 14:38
Psoriasis and Biologics: The Beat Goes On Presented ByProf. Mark Lebwohl, Mount Sinai School of Medicine, USA ConferenceAAD 2019 19 April, 2019 14:06
Living in the golden age of psoriasis and atopic dermatitis therapies ExpertDr Erik Joseph Stratman, Marshfield Clinic, Wisconsin, USA ConferenceAAD 2018 21 December, 2018 16:46
Psoriasis: Selective IL-23 blocker, analysis of VOYAGE-2, dual IL-17 inhibitor and ustekinumab Presented ByProf. Kenneth Gordon, Medical College of Wisconsin, USA; Prof. Kristian Reich, SCIderm Research Institute, Germany; Dr Kim Papp, Probity Medical Research, Canada; Prof. Joel Gelfand, University of Pennsylvania Perelman School of Medicine, USA ConferenceAAD 2018 20 December, 2018 15:30